West Face Capital Exercises Control over Shares of Chieftain Metals

West Face Capital Inc. ("WFCI"), announced today that it acquired control of 550,000 common shares of Chieftain Metals Inc. (the "Issuer") purchased by a fund managed by WFCI.

The purchase was made pursuant to the Issuer's initial public offering by prospectus dated December 16, 2010 at $5.00 per common share and did not take place on a published market.

WFCI exercises control and direction over 2,162,250 common shares and 806,125 warrants to purchase common shares of the Issuer. These securities include 1,400,000 common shares and 700,000 warrants owned by WFC (Lux1 S.à.r.l.) ("WFC Lux") and securities owned by other funds managed by WFCI. Certain of those funds own all the outstanding securities of WFC Lux.

WFCI and WFC Lux have a securityholding percentage, calculated in accordance with National Instrument 62-103 The Early Warning System and Related Take-Over Bid and Insider Reporting Issues of approximately 24.9% and 17.8%, respectively.

The securities of the Issuer were acquired by WFCI and WFC Lux for investment purposes. Each of WFCI and WFC Lux expects to review from time to time its investment in the Issuer and may, depending on the market and other conditions: (i) acquire securities or related financial instruments of the Issuer in the open market, in privately negotiated transactions or otherwise, and/or (ii) dispose of all or a portion of the securities or related financial instruments of the Issuer over which it now or hereafter exercises, or may be deemed to exercise, control or direction, or owns.

The issuance of this news release is not an admission that any entity named herein owns or controls any described securities or is a joint actor with another named entity.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.